Bristol-Myers Squibb employees ride across the U.S. to raise money to support cancer research by Stand Up To Cancer

Bristol-Myers SquibbThe first of seven teams of Bristol-Myers Squibb (NYSE:BMY) employees mounted their bikes in Cannon Beach, OR, today to kick off the 2017 Coast 2 Coast 4 Cancer Ride. Ninety-three novice riders will bike a total of nearly 2,800 miles during the 21-day mission to raise money and awareness for Stand Up To Cancer’s innovative cancer research programs that bring together collaborative teams of scientific researchers to help get new therapies to patients faster.

Bristol-Myers Squibb will match funds raised during the 2017 Coast 2 Coast 4 Cancer Ride dollar-for-dollar up to a total of $500,000. This is the fourth Coast 2 Coast 4 Cancer Ride benefitting Stand Up To Cancer (SU2C). Last year’s Coast 2 Coast 4 Cancer ride raised over $1 million for SU2C research programs.

Katie Couric, award-winning journalist and SU2C co-founder said, "All of us at Stand Up To Cancer are profoundly grateful to the Bristol-Myers Squibb employees as they cycle cross-country. Their commitment honors those who are fighting cancer, as well as those lost to the disease. The riders - and everyone who supports them - are helping SU2C advance research with the hope of one day turning more and more cancer patients into long-term survivors."

This year, Bonni Norwood of Spring Lakes, MI, a cancer survivor herself who hasn’t ridden a bike in 45 years, will ride from Kansas City, MO, to Indianapolis, IN. "While training to ride 75 miles per day is difficult for me, my struggles pale in comparison to those faced by people fighting cancer," said Bonni. "I'm riding for two dear friends who are both young and vibrant, but are currently battling cancer. When I face steep climbs or cross winds, I will dig deep and persevere for them and for all cancer patients."

"Every day, we, at Bristol-Myers Squibb, challenge ourselves individually and collectively as a team to fight cancer," said Teresa Bitetti, senior vice president, U.S. Oncology, Bristol-Myers Squibb. "Our employees who are riding across the country exemplify this passion and purpose - to help drive real change for people impacted by cancer."

Concurrently, seventy-eight Bristol-Myers Squibb employees in Europe will embark on a Country 2 Country 4 Cancer Ride . The Country 2 Country Ride kicks off September 8 in Germany, and spans 3,600 kilometers (2,236 miles) through Switzerland, Italy, France, Spain, and the United Kingdom. Funds raised will support one of eight market-specific cancer-focused charities in Europe.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

About Stand Up To Cancer
Stand Up To Cancer (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a division of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization, was established in 2008 by film and media leaders who utilize the industry’s resources to engage the public in supporting a new, collaborative model of cancer research, and to increase awareness about cancer prevention as well as progress being made in the fight against the disease. As SU2C's scientific partner, the American Association for Cancer Research (AACR) and a Scientific Advisory Committee led by Nobel Laureate Phillip A. Sharp, PhD, conduct rigorous, competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and provide expert review of research progress.

Current members of the SU2C Council of Founders and Advisors (CFA) include Katie Couric, Sherry Lansing, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, Ellen Ziffren, and Kathleen Lobb. The late Laura Ziskin and the late Noreen Fraser are also co-founders. Sung Poblete, PhD, RN, has served as SU2C’s president and CEO since 2011.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Consuming milk at breakfast lowers blood glucose t…

A change in breakfast routine may provide benefits for the management of type 2 diabetes, according to a new study published in the Journal of Dairy Science. H. Douglas G...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...